Inhibikase Therapeutics (IKT) Total Debt (2020 - 2025)
Historic Total Debt for Inhibikase Therapeutics (IKT) over the last 6 years, with Q2 2025 value amounting to $37944.0.
- Inhibikase Therapeutics' Total Debt fell 7507.36% to $37944.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $37944.0, marking a year-over-year decrease of 7507.36%. This contributed to the annual value of $110517.0 for FY2024, which is 2636.86% down from last year.
- Inhibikase Therapeutics' Total Debt amounted to $37944.0 in Q2 2025, which was down 7507.36% from $74772.0 recorded in Q1 2025.
- In the past 5 years, Inhibikase Therapeutics' Total Debt registered a high of $248911.0 during Q1 2021, and its lowest value of $37944.0 during Q2 2025.
- Its 5-year average for Total Debt is $146537.4, with a median of $147433.5 in 2023.
- In the last 5 years, Inhibikase Therapeutics' Total Debt soared by 491.52% in 2023 and then tumbled by 7507.36% in 2025.
- Inhibikase Therapeutics' Total Debt (Quarter) stood at $248911.0 in 2021, then plummeted by 41.41% to $145836.0 in 2022, then grew by 2.92% to $150095.0 in 2023, then fell by 26.37% to $110517.0 in 2024, then plummeted by 65.67% to $37944.0 in 2025.
- Its last three reported values are $37944.0 in Q2 2025, $74772.0 for Q1 2025, and $110517.0 during Q4 2024.